Hints and tips:
Related Special Reports
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...“Pfizer’s investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva’s vaccine expertise,” Valneva chief executive Thomas...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Thomas Cueni, the director-general of the International Federation of Pharmaceutical Manufacturers & Associations, said the IP waiver would have been a “distraction”....
...Thomas Cueni, director-general of the International Federation of Pharmaceutical Manufacturers & Associations, says it is up to governments with surplus doses like the US, UK, EU and Canada to make sure...
...Pfizer and BioNTech started enrolling participants in their phase 1 study in September....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Thomas Lingelbach, Valneva chief executive, said it was aiming to produce 150m to 200m doses a year. “Of course we are not going to be the ones to produce billions of doses....
...You don’t have to be Thomas Piketty to recognise that inequality poses a significant risk to the global system as it stands....
...“A lot of people in town are just a tiny little bit proud that we have been offered this role,” said mayor Thomas Spies. “But we were not so surprised as we have a long tradition in vaccination.”...
...‘Once bitten, twice shy’ Before the pandemic, Pfizer and Sanofi had both begun to dabble in mRNA vaccines through partnerships — but Pfizer’s partner BioNTech was far further along than Sanofi’s partner...
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Lynn Thomas, medical director for St John Ambulance, a charity, said the organisation had been asked to supply 30,500 people to support up to 100 mass vaccination centres....
...— used in the BioNTech/Pfizer and Moderna jabs — is running in its favour....
...Thomas Mertens, the head of Germany’s vaccine committee, told DPA news agency last week that extending the gap between doses was “definitely worth considering”....
...‘Perfect scenario’ Those look like V-shaped projections, Andrew Glenn thought to himself....
...“Vaccine makers have committed to publish all the clinical trails in peer-reviewed publications . . . to an extent like never before; whether they are good or bad,” said Thomas Cueni, head of the International...
...Brunswick Group hired former Pfizer China government affairs vice-president Xi Qing as a partner in Asia....
...That could risk a backlash against their adoption — a concern for vaccines such as Russia’s Sputnik V and Sinopharm’s in China, which are already being provided to the public before large-scale testing is...
...The EU medicines regulator has approved Pfizer/BioNTech’s Covid-19 vaccine. Germany and Switzerland halted flights from South Africa over the new virus strain....
...Thomas Hale 98....
...“After months of apologising for getting this story so wrong, we are relieved and not entirely surprised,” said Thomas Shrader, an analyst at BTIG....
...DD’s Indap v NYU’s Damodaran: Is stock compensation good or bad?...
...The 1984 case, formally known as “Chevron USA Inc v Natural Resources Defense Council Inc” formalised the legal doctrine that requires judges to defer to administrative agencies’ interpretation of federal...
International Edition